' 
SCIENTIFIC SCORE
Most Likely Effective
Based on 32 Researches
7.5
USERS' SCORE
Very Good
Based on 1 Reviews
7
Supplement Facts
Serving Size: 1 Softgel
Amount Per Serving
%DV
Calories
10
Total Fat
1 g
1%**
Saturated Fat
< 0.5 g
2%**
Polyunsaturated Fat
0.5 g
†
Fish Oil Concentrate
1 g (1,000 mg)
†
Omega-3 Fatty Acids:
Eicosapentaenoic Acid (EPA)
180 mg
†
Docosahexaenoic Acid (DHA)
120 mg
†
Top Medical Research Studies
9
DHA impacts breast cancer immunity
Docosahexaenoic acid (DHA) impairs hypoxia-induced cellular and exosomal overexpression of immune-checkpoints and immunomodulatory molecules in different subtypes of breast cancer cells.
Directly relevant DHA effects
We explored the role of docosahexaenoic acid (DHA), an omega-3 fatty acid, in altering the behavior of breast cancer cells, specifically focusing on how it impacts immune responses. Cancer cells often use immune-checkpoint molecules to evade our body’s natural defenses, and this study looked at whether DHA could influence the expression of these critical molecules.
By treating two types of breast cancer cells—MDA-MB-231 (triple negative) and BT-474 (triple positive)—with DHA under both normoxic and hypoxic (low oxygen) conditions for 24 hours, we observed notable changes. The study showed that hypoxia caused a significant increase in immune-checkpoints and immunomodulatory molecules. However, when we introduced DHA, the results were promising: there was a marked decrease in the expression of those immune markers.
Additionally, the treatment with DHA also led to an increase in regulatory microRNAs, which are important for controlling the immune response. These results suggest that DHA might play a supportive role in breast cancer therapy by reducing the mechanisms that allow cancer cells to escape immune surveillance. This could open pathways for new treatment options that integrate nutritional interventions like DHA supplementation alongside traditional cancer therapies.
By treating two types of breast cancer cells—MDA-MB-231 (triple negative) and BT-474 (triple positive)—with DHA under both normoxic and hypoxic (low oxygen) conditions for 24 hours, we observed notable changes. The study showed that hypoxia caused a significant increase in immune-checkpoints and immunomodulatory molecules. However, when we introduced DHA, the results were promising: there was a marked decrease in the expression of those immune markers.
Additionally, the treatment with DHA also led to an increase in regulatory microRNAs, which are important for controlling the immune response. These results suggest that DHA might play a supportive role in breast cancer therapy by reducing the mechanisms that allow cancer cells to escape immune surveillance. This could open pathways for new treatment options that integrate nutritional interventions like DHA supplementation alongside traditional cancer therapies.
Read More
8
Eicosapentaenoic acid lowers breast cancer risk
Erythrocyte membrane -3 PUFA are inversely associated with breast cancer risk among Chinese women.
Focus on EPA's effects explored
We aimed to explore the connection between eicosapentaenoic acid (EPA) and the risk of breast cancer among Chinese women through a careful study design. Our research involved 853 women newly diagnosed with breast cancer and 892 healthy control participants who matched their age and characteristics. Using advanced techniques, we measured levels of omega-3 fatty acids in the erythrocyte membranes of those involved.
Our findings revealed that higher levels of erythrocyte membrane EPA correlated with a significantly reduced risk of developing breast cancer. Specifically, we observed that the odds of breast cancer were 41% lower for those with the highest levels of EPA when compared to those with the lowest. In addition, we also noted a favorable association with another omega-3 fatty acid, docosahexaenoic acid (DHA), which showed a similar trend.
Interestingly, these protective effects of EPA and DHA were even more marked in postmenopausal women and those with estrogen receptor-positive breast cancer. Overall, our study suggests that maintaining higher levels of eicosapentaenoic acid could benefit women by potentially lowering their breast cancer risk. We believe that other factors like menopause status and hormone receptor type should be considered for further research into omega-3 fatty acids and breast cancer.
Our findings revealed that higher levels of erythrocyte membrane EPA correlated with a significantly reduced risk of developing breast cancer. Specifically, we observed that the odds of breast cancer were 41% lower for those with the highest levels of EPA when compared to those with the lowest. In addition, we also noted a favorable association with another omega-3 fatty acid, docosahexaenoic acid (DHA), which showed a similar trend.
Interestingly, these protective effects of EPA and DHA were even more marked in postmenopausal women and those with estrogen receptor-positive breast cancer. Overall, our study suggests that maintaining higher levels of eicosapentaenoic acid could benefit women by potentially lowering their breast cancer risk. We believe that other factors like menopause status and hormone receptor type should be considered for further research into omega-3 fatty acids and breast cancer.
Read More
8
DHA's effects on breast cancer
Lysophosphatidylcholine-DHA Specifically Induces Cytotoxic Effects of the MDA-MB-231 Human Breast Cancer Cell Line -Comparative Effects with Other Lipids Containing DHA.
Highly relevant to breast cancer
We explored how different forms of docosahexaenoic acid (DHA), a beneficial fatty acid linked to reduced cancer risk, affect the viability of MDA-MB-231 breast cancer cells. Specifically, we investigated the effects of free DHA and five different lipid carriers containing DHA, including LPC-DHA, PC-DHA, MAG-DHA, DAG-DHA, and TAG-DHA.
Our findings revealed a notable pattern: glycerophosphocholine-based lipids, particularly LPC-DHA, were the most effective at harming cancer cells. We observed that LPC-DHA had a lower effective concentration (IC = 23.7 µM) compared to PC-DHA (IC = 67 µM). The other tested lipids, such as MAG-DHA and free DHA, showed less cytotoxicity, while DAG-DHA and TAG-DHA did not reduce cell viability at all.
Upon further investigation, we learned that LPC-DHA might induce cell death through increased oxidative stress and damage to the cell membranes. This highlights the importance of the lipid carrier in delivering DHA to cancer cells effectively, suggesting a potential avenue for future therapeutic strategies.
Our findings revealed a notable pattern: glycerophosphocholine-based lipids, particularly LPC-DHA, were the most effective at harming cancer cells. We observed that LPC-DHA had a lower effective concentration (IC = 23.7 µM) compared to PC-DHA (IC = 67 µM). The other tested lipids, such as MAG-DHA and free DHA, showed less cytotoxicity, while DAG-DHA and TAG-DHA did not reduce cell viability at all.
Upon further investigation, we learned that LPC-DHA might induce cell death through increased oxidative stress and damage to the cell membranes. This highlights the importance of the lipid carrier in delivering DHA to cancer cells effectively, suggesting a potential avenue for future therapeutic strategies.
Read More
Most Useful Reviews
7
Effective treatment
The quality of the product is excellent. I always consume Omega, which aids in preventing breast cancer, and Hedicalmback, which promotes healing in the body.
Read More
Most Recommended Products for Breast Cancer
Thorne Ultimate-E®
SCIENTIFIC SCORE
No researches found
N/A
USERS' SCORE
Excellent
Based on 1 Reviews
9.5
Nature's Way Mega-Zyme
SCIENTIFIC SCORE
No researches found
N/A
USERS' SCORE
Excellent
Based on 5 Reviews
9.3
American Health Ester-C with Citrus Bioflavonoids
SCIENTIFIC SCORE
No researches found
N/A
USERS' SCORE
Excellent
Based on 2 Reviews
9.2
Medical Researches
SCIENTIFIC SCORE
Most Likely Effective
Based on 32 Researches
7.5
9.5
Effective DHA and DTX combination
Improved Antitumor Efficacy of a Dextran-based Docetaxel-coupled Conjugate against Triple-Negative Breast Cancer.
Relevant to DHA's cancer effects
We explored the effectiveness of a new treatment strategy for breast cancer that combines docosahexaenoic acid (DHA) with docetaxel (DTX). In our study, we developed a dextran-based dual-drug conjugate that allows these two compounds to work together more effectively against breast cancer cells.
The conjugate we created showed promise in our tests, especially against triple-negative breast cancer, which is often more challenging to treat. We discovered that this new formulation not only improved the water solubility of DTX but also enabled it to reach the tumor more effectively, minimizing distribution to normal tissues.
Results demonstrated that this combination significantly inhibited tumor growth compared to traditional DTX treatments, nearly eliminating tumors in our mouse model without causing adverse systemic effects. This work suggests that when DHA is coupled with DTX, it enhances the potential for improved breast cancer treatments.
The conjugate we created showed promise in our tests, especially against triple-negative breast cancer, which is often more challenging to treat. We discovered that this new formulation not only improved the water solubility of DTX but also enabled it to reach the tumor more effectively, minimizing distribution to normal tissues.
Results demonstrated that this combination significantly inhibited tumor growth compared to traditional DTX treatments, nearly eliminating tumors in our mouse model without causing adverse systemic effects. This work suggests that when DHA is coupled with DTX, it enhances the potential for improved breast cancer treatments.
Read More
9
Eicosapentaenoic Acid inhibits BCSC growth
Increased lipogenesis is critical for self-renewal and growth of breast cancer stem cells: Impact of omega-3 fatty acids.
Relevant study on fatty acids
We investigated how eicosapentaenoic acid (EPA), part of the omega-3 fatty acids family, influences breast cancer stem cells (BCSC). Using specialized in vitro models derived from mammosphere cultures, we observed that BCSCs exhibited a unique fatty acid metabolism, especially in lipogenesis, which is the process of creating fats.
One of the key enzymes, stearoyl-CoA desaturase 1 (SCD1), was especially active in these cells, promoting their growth and ability to self-renew. When we inhibited SCD1, whether through specific drugs or small interfering RNA (siRNA) techniques, we noticed a significant reduction in both growth and self-renewal of the BCSCs. This indicates SCD1 plays an essential role in their survival.
Moreover, we discovered elevated SCD1 and related lipogenic enzymes in human breast cancer tissues, pointing to their correlation with tumor grade. Notably, when we treated BCSCs with EPA, we found a decrease in the expression of lipogenic enzymes, leading to reduced self-renewal and growth of these cancer stem cells. In animal models, dietary EPA also resulted in a significant reduction of tumor load, showcasing its potential as a therapeutic avenue.
Overall, our findings highlight the critical role of increased lipogenesis in the growth and maintenance of BCSCs, and they suggest that EPA could be a valuable player in targeting this process to combat breast cancer.
One of the key enzymes, stearoyl-CoA desaturase 1 (SCD1), was especially active in these cells, promoting their growth and ability to self-renew. When we inhibited SCD1, whether through specific drugs or small interfering RNA (siRNA) techniques, we noticed a significant reduction in both growth and self-renewal of the BCSCs. This indicates SCD1 plays an essential role in their survival.
Moreover, we discovered elevated SCD1 and related lipogenic enzymes in human breast cancer tissues, pointing to their correlation with tumor grade. Notably, when we treated BCSCs with EPA, we found a decrease in the expression of lipogenic enzymes, leading to reduced self-renewal and growth of these cancer stem cells. In animal models, dietary EPA also resulted in a significant reduction of tumor load, showcasing its potential as a therapeutic avenue.
Overall, our findings highlight the critical role of increased lipogenesis in the growth and maintenance of BCSCs, and they suggest that EPA could be a valuable player in targeting this process to combat breast cancer.
Read More
9
Eicosapentaenoic Acid Enhances Chemotherapy
Nutritional supplements in combination with chemotherapy or targeted therapy reduces tumor progression in mice bearing triple-negative breast cancer.
Supports effects of EPA in cancer
We explored how eicosapentaenoic acid (EPA), a nutritional supplement, works alongside chemotherapy agents like Taxol, Adriamycin, and Avastin to manage triple-negative breast cancer (TNBC) in mice. In our study, we compared the effects of these treatments on tumor growth and metastasis.
We observed that while the chemotherapy alone led to reduced tumor size and a lower chance of cancer spreading, the combination of these drugs with EPA significantly boosted these effects. Notably, the addition of a small dose (5.1 mg of EPA along with selenium) resulted in even greater reductions in tumor progression and spread.
Furthermore, this combination therapy altered immune responses by increasing certain beneficial cytokines while decreasing others that are usually associated with tumor growth. Interestingly, we saw a rise in apoptotic proteins, which are critical for programmed cell death of cancer cells. Additionally, levels of PD-L1, an immune checkpoint protein, decreased, which could help the immune system better target the cancer.
Overall, our findings suggest that combining low-dose chemotherapy with EPA has the potential to enhance anti-cancer effects significantly. This approach may be a promising avenue for treatment options in managing TNBC.
We observed that while the chemotherapy alone led to reduced tumor size and a lower chance of cancer spreading, the combination of these drugs with EPA significantly boosted these effects. Notably, the addition of a small dose (5.1 mg of EPA along with selenium) resulted in even greater reductions in tumor progression and spread.
Furthermore, this combination therapy altered immune responses by increasing certain beneficial cytokines while decreasing others that are usually associated with tumor growth. Interestingly, we saw a rise in apoptotic proteins, which are critical for programmed cell death of cancer cells. Additionally, levels of PD-L1, an immune checkpoint protein, decreased, which could help the immune system better target the cancer.
Overall, our findings suggest that combining low-dose chemotherapy with EPA has the potential to enhance anti-cancer effects significantly. This approach may be a promising avenue for treatment options in managing TNBC.
Read More
9
DHA impacts breast cancer survivors
Randomized dose-response trial of n-3 fatty acids in hormone receptor negative breast cancer survivors- impact on breast adipose oxylipin and DNA methylation patterns.
Direct investigation of DHA effects
We investigated how docosahexaenoic acid (DHA), along with eicosapentaenoic acid (EPA), affects women who have survived hormone receptor-negative (ERPR-) breast cancer. Our study focused on a randomized controlled trial involving participants who had completed standard treatment within the past five years. We compared the effects of two different doses of DHA and EPA supplementation over a year—one higher at around 5 grams per day and another lower at about 1 gram per day.
Throughout the 12-month period, we collected blood and breast adipose tissue samples every three months to analyze various biomarkers. What we observed was a dose-dependent increase in the levels of these fatty acids and their biological metabolites, known as oxylipins. Notably, this increase corresponded with changes in DNA methylation patterns in the gene promoters associated with metabolism pathways that are crucial in the development and progression of ERPR- breast cancer.
Our findings suggest that high doses of EPA and DHA not only influence the fatty acid profiles in breast adipose tissue but also impact genetic expression linked with breast cancer progression. This research opens new avenues for understanding how n-3 fatty acids could play a role in preventing ERPR- breast cancer through both metabolic and epigenetic means.
Throughout the 12-month period, we collected blood and breast adipose tissue samples every three months to analyze various biomarkers. What we observed was a dose-dependent increase in the levels of these fatty acids and their biological metabolites, known as oxylipins. Notably, this increase corresponded with changes in DNA methylation patterns in the gene promoters associated with metabolism pathways that are crucial in the development and progression of ERPR- breast cancer.
Our findings suggest that high doses of EPA and DHA not only influence the fatty acid profiles in breast adipose tissue but also impact genetic expression linked with breast cancer progression. This research opens new avenues for understanding how n-3 fatty acids could play a role in preventing ERPR- breast cancer through both metabolic and epigenetic means.
Read More
9
DHA impacts breast cancer immunity
Docosahexaenoic acid (DHA) impairs hypoxia-induced cellular and exosomal overexpression of immune-checkpoints and immunomodulatory molecules in different subtypes of breast cancer cells.
Directly relevant DHA effects
We explored the role of docosahexaenoic acid (DHA), an omega-3 fatty acid, in altering the behavior of breast cancer cells, specifically focusing on how it impacts immune responses. Cancer cells often use immune-checkpoint molecules to evade our body’s natural defenses, and this study looked at whether DHA could influence the expression of these critical molecules.
By treating two types of breast cancer cells—MDA-MB-231 (triple negative) and BT-474 (triple positive)—with DHA under both normoxic and hypoxic (low oxygen) conditions for 24 hours, we observed notable changes. The study showed that hypoxia caused a significant increase in immune-checkpoints and immunomodulatory molecules. However, when we introduced DHA, the results were promising: there was a marked decrease in the expression of those immune markers.
Additionally, the treatment with DHA also led to an increase in regulatory microRNAs, which are important for controlling the immune response. These results suggest that DHA might play a supportive role in breast cancer therapy by reducing the mechanisms that allow cancer cells to escape immune surveillance. This could open pathways for new treatment options that integrate nutritional interventions like DHA supplementation alongside traditional cancer therapies.
By treating two types of breast cancer cells—MDA-MB-231 (triple negative) and BT-474 (triple positive)—with DHA under both normoxic and hypoxic (low oxygen) conditions for 24 hours, we observed notable changes. The study showed that hypoxia caused a significant increase in immune-checkpoints and immunomodulatory molecules. However, when we introduced DHA, the results were promising: there was a marked decrease in the expression of those immune markers.
Additionally, the treatment with DHA also led to an increase in regulatory microRNAs, which are important for controlling the immune response. These results suggest that DHA might play a supportive role in breast cancer therapy by reducing the mechanisms that allow cancer cells to escape immune surveillance. This could open pathways for new treatment options that integrate nutritional interventions like DHA supplementation alongside traditional cancer therapies.
Read More
User Reviews
USERS' SCORE
Very Good
Based on 1 Reviews
7
7
Effective treatment
The quality of the product is excellent. I always consume Omega, which aids in preventing breast cancer, and Hedicalmback, which promotes healing in the body.
